Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
LaDuane Clifton, Zevra’s Chief Financial Officer said, “This non-dilutive capital strengthens our balance sheet by adding gross cash proceeds of $150 million, supporting continued investment in our ...
Zevra Therapeutics to sell Rare Pediatric Disease PRV for $150M
Zevra Therapeutics (ZVRA) has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ...
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
Zevra Therapeutics has inked a deal to sell its Food and Drug Administration priority-review voucher to an undisclosed buyer for gross proceeds of $150 million.
FiercePharma21h
Zevra to net $150M from priority review voucher sale tied to Miplyffa approval
For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that ...
Investing17h
Zevra Therapeutics stock rises on $150M asset sale
Investing.com -- Shares of Zevra Therapeutics, Inc. ( Nasdaq: ZVRA) climbed 8% following the announcement that the company has entered into an agreement to sell its Rare Pediatric Disease Priority ...
GlobalData on MSN12h
Zevra sells priority review voucher for $150m to support drug launches
Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party. The ...
The Pharma Letter18h
BRIEF—Zevra sells Miplyffa-linked PRV for $150 million
Rare disease-focused biopharma Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $150 million.
BioSpace6h
6 Rare Diseases That Have New FDA-Approved Treatments
ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...